Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07029776 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Jul 1, 2026 to Mar 1, 2027v6
  2. Start date: Apr 1, 2026 to Jul 1, 2026v5
  3. Start date: Oct 1, 2025 to Apr 1, 2026v4
  4. Start date: Jul 1, 2025 to Oct 1, 2025v3
  5. Re-verified, no change to tracked fieldsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this research is to learn whether using teclistamab and talquetamab at different time points will improve survival in participants with high-risk Multiple Myeloma (MM). The treatment on this study will consist of Induction chemotherapy and stem cell collection, Immunotherapy 1 chemotherapy and Immunotherapy 2 chemotherapy. For participants whose testing show they are Minimal Residual Disease (MRD) positive (still have myeloma cells present in the bone marrow testing), a Melphalan-based stem cell transplant will be performed. For participants whose testing show they are MRD negative, the stem cell transplant will not be performed. All participants will go on to receive Immunotherapy 3 chemotherapy, Immunotherapy 4 chemotherapy, and Maintenance therapy.
Trial Details
NCT Number NCT07029776
Lead Sponsor University of Arkansas
Collaborators: Janssen Research & Development, LLC
Conditions
(from sponsor)		 Multiple Myeloma (MM)
Related terms Multiple Myeloma
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov